Hindustan Unilever Ltd. on Friday filed a writ petition in the Bombay High Court challenging an assessment order worth Rs 963 crore, received in August 2024. The company filed a writ petition before the Bombay High Court challenging the assessment order and the accompanying demand notice issued by the Income Tax Authorities, according to a statement to the exchanges.
"This is further to our letter dated Aug. 26, 2024, intimating about the Assessment Order dated Aug. 23, 2024, whereby a demand of Rs 962.75 crores (including interest of Rs 329.33 crores) was raised on the company on account of non-deduction of TDS while making remittance for payment towards acquisition of India HFD IPR from GlaxoSmithKline ‘GSK' Group entities," according to the statement.
The statement comes after the FMCG company received a demand of Rs 962.75 crore from the Income Tax Department on account of non-deduction of tax deducted at source as per tax laws last month. The demand includes interest of Rs 329.3 crore.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
The tax demand pertains to the TDS not paid on a remittance of Rs 3,045 crore (375.6 million euro) for payment towards acquisition of India HFD IPR from GlaxoSmithKline ‘GSK' Group entities.
HUL had acquired GlaxoSmithKline's health-food-drinks (HFD) portfolio, which includes the Horlicks brand, in 2018. This acquisition covered India, Bangladesh, and 20 other predominantly Asian markets.
Shares of HUL closed 0.60% lower at Rs 2,938.70 apiece, compared to a 0.13% decline in the NSE Nifty 50 Index on Friday. The stock has returned 19.3% so far this year.
Twenty-four out of 42 analysts tracked by Bloomberg had a 'buy' call on the stock, while 13 analysts had a 'hold' call and five had a 'sell' rating. The analyst consensus 12-month price target tracked by Bloomberg was Rs 2,899.20, implying a potential decline of 1.2% from the last closing price.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.